A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)

NCT05984238 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DEVICE: ReCET
DRUG: Semaglutide, 1.0 mg/mL
OTHER: Sham procedure

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Collaborators

[object Object]